Antony Mattessich
Director/Board Member at AURA BIOSCIENCES, INC.
Net worth: 5 M $ as of 30/03/2024
Profile
Antony Mattessich is an Independent Non-Executive Director at Aura Biosciences, Inc. He previously served as President, Chief Executive Officer & Director at Mundipharma International Ltd.
from 2009 to 2017.
From 2017 to 2024, he held the same positions at Ocular Therapeutix, Inc. Prior to that, he was the Managing Director & Director at Napp Pharmaceutical Holdings Ltd.
from 2005 to 2011.
Antony also worked at Bristol Myers Squibb Co. as the Head of Operations-International Medicines.
Before that, he was the Head-Therapeutic Franchise at Novartis AG from 2003 to 2005.
Antony completed his graduate degree at The Trustees of Columbia University in The City of New York and his undergraduate degree at the University of California, Berkeley.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
OCULAR THERAPEUTIX INC
0.40% | 04/02/2024 | 595,201 ( 0.40% ) | 5 M $ | 30/03/2024 |
AURA BIOSCIENCES INC
-.--% | 06/06/2023 | 0 ( -.--% ) | - $ | 30/03/2024 |
Antony Mattessich active positions
Companies | Position | Start |
---|---|---|
AURA BIOSCIENCES, INC. | Director/Board Member | 28/09/2021 |
Former positions of Antony Mattessich
Companies | Position | End |
---|---|---|
OCULAR THERAPEUTIX, INC. | Chief Executive Officer | 14/04/2024 |
Mundipharma International Ltd.
Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Mundipharma International Ltd. develops and produces pharmaceutical products. It offers analgesics, oncology, respiratory, gastrointestinal, and cardiovascular drugs. The company was founded in 1952 and is headquartered in Cambridge, the United Kingdom. | Chief Executive Officer | 17/12/2017 |
Napp Pharmaceutical Holdings Ltd.
Napp Pharmaceutical Holdings Ltd. Pharmaceuticals: MajorHealth Technology Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom. | Chief Executive Officer | 30/04/2011 |
NOVARTIS AG | Corporate Officer/Principal | 31/12/2004 |
BRISTOL-MYERS SQUIBB COMPANY | Director/Board Member | - |
Training of Antony Mattessich
The Trustees of Columbia University in The City of New York | Graduate Degree |
University of California, Berkeley | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
OCULAR THERAPEUTIX, INC. | Health Technology |
AURA BIOSCIENCES, INC. | Health Technology |
NOVARTIS AG | Health Technology |
Private companies | 2 |
---|---|
Mundipharma International Ltd.
Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Mundipharma International Ltd. develops and produces pharmaceutical products. It offers analgesics, oncology, respiratory, gastrointestinal, and cardiovascular drugs. The company was founded in 1952 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Napp Pharmaceutical Holdings Ltd.
Napp Pharmaceutical Holdings Ltd. Pharmaceuticals: MajorHealth Technology Napp Pharmaceutical Holdings Ltd. develops and provides medicines to patients. It offers prescription products for respiratory diseases such as asthma, inflammatory conditions, Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and psoriasis, as well as pain management, blood cancers, and cardiovascular conditions. The company was founded on December 19, 1997 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Antony Mattessich